English
Spanish
French
Italian
German
NEWS ARCHIVE
Explore our archive of news and updates from the HS Foundation — a curated collection of stories, milestones, and announcements from over the years.
Bimekizumab Shows Durable Responses in Psoriasis and HS Through 3 Years
Yesterday
New long‑term data presented at the 2026 AAD Annual Meeting suggest bimekizumab delivers durable disease control in hidradenitis suppurativa, with a growing proportion of patients remaining flare‑free through 3 years and no new safety signals observed. In this brief interview, Steven Daveluy, MD, discusses why extended assessment periods matter in HS, how sustained response influences treatment confidence, and what these findings may mean for long‑term patient care.
Read more
Advancing Hidradenitis Suppurativa Care: Expert Perspectives on Diagnosis, Treatment, and Patient Impact
May 16, 2026
In this Dermatology Times video series, board-certified dermatologists Dr. Jennifer Hsiao and Dr. Barry Resnik take a comprehensive look at Hidradenitis Suppurativa—from the multidimensional burden and diagnostic challenges to evolving therapies like JAK inhibitors. Through expert insights and practical guidance, this series equips dermatologists to recognize HS earlier, address misconceptions, build patient trust, and improve long-term outcomes.
Read more
Hidradenitis Suppurativa Explained: From Pain and Stigma to Promising New Treatments
May 13, 2026
What exactly is Hidradenitis Suppurativa (HS), and why is it so often misunderstood? On this episode of Science of Skin, dermatologist Dr. Ted Lain and HS expert Dr. Steve Daveluy unpack the biology, burden, and breakthrough therapies shaping the future of HS care.
Read more
New Hope for Adolescents with Hidradenitis Suppurativa
May 11, 2026
A new chapter in care for teens with hidradenitis suppurativa is emerging. With the FDA approval of an additional biologic option, dermatologists now have greater flexibility to intervene earlier, tailor treatment, and potentially prevent lifelong scarring and disease progression. Experts explain why timing matters, how treatment strategies are evolving, and what this milestone could mean for young patients and their families—read on to explore the promise behind this breakthrough.
Read more
Avalo Therapeutics Reports Positive Phase 2 Results for Abdakibart in Hidradenitis Suppurativa
May 7, 2026
Avalo Therapeutics announced positive topline results from its Phase 2 LOTUS clinical trial evaluating abdakibart (AVTX‑009) in adults with moderate to severe hidradenitis suppurativa, supporting continued development toward a Phase 3 program.
Read more
Managing the Psychological Toll of HS
April 24, 2026
Living with hidradenitis suppurativa can take a serious emotional toll—from anxiety and depression to challenges with self-esteem, relationships, and daily life. This article explores why mental health support is a critical part of HS care and offers insight into recognizing, addressing, and treating the psychological burden of the disease. Click to read why caring for your mind matters as much as caring for your skin.
Read more
Understanding Hidradenitis Suppurativa: What You Need to Know
April 24, 2026
Painful lumps, flare-ups in skin folds, delayed diagnosis—hidradenitis suppurativa can be confusing, frustrating, and life-altering. This patient-friendly FAQ explains what HS is (and what it isn’t), who is at risk, why it’s so often misdiagnosed, and what treatment options are available. Click to learn the essential facts every person living with HS should know.
Read more
From Reactive to Proactive: Building Longitudinal Care Plans That Actually Work for Hidradenitis Suppurativa
April 17, 2026
What if dermatologic care didn’t stop at the flare? Discover why shifting from reactive treatment to proactive, longitudinal care plans can lead to better outcomes, stronger patient relationships, and management strategies that truly stand the test of time.
Read more
Beyond the Surface: April 2026
April 10, 2026
Catch the latest from the Hidradenitis Suppurativa Foundation—Board leadership updates, new HS research insights, upcoming clinical guidelines, featured resources, and key events on the horizon.
Read more
Expert Insights on HS: What Every Patient Should Know About Today’s Treatment Landscape
April 1, 2026
In a new episode of the Derms on Drugs podcast, leading dermatology experts discuss the evolving understanding of hidradenitis suppurativa, including treatment strategies, emerging therapies, and what real progress looks like for patients. Tune in to hear practical insights that shed light on where HS care is headed and how it continues to change lives.
Read more
A New Era of Hope for HS: Personalized Treatments Are Changing the Outlook
March 31, 2026
What if HS care could be tailored to you? At the 2026 AAD Annual Meeting, dermatology experts shared how personalized combinations of medical and in‑office surgical treatments are improving outcomes and bringing new hope to people living with moderate to severe hidradenitis suppurativa. Learn how these advances could shape the future of HS care and why they matter now.
Read more
Raising the Bar for HS Outcomes With Barry Resnik, MD
March 15, 2026
Years-long diagnostic delays and incremental treatment approaches have left many patients struggling. Barry Resnik shares how earlier escalation, clearer treatment goals, and a focus on function, not just lesions, could change the trajectory of hidradenitis suppurativa care.
Read more
Standardization of Lesion Classification and Assessment by Investigators in Clinical Trials for Hidradenitis Suppurativa
March 5, 2026
A team of dermatology experts has just agreed on a standardized way to identify and classify HS lesions, potentially transforming how clinical trials measure disease and evaluate treatments. Find out how this new consensus could reshape research and bring us closer to better therapies.
Read more
Understanding Moderate Hidradenitis Suppurativa: Diagnosis, Impact, and Treatment
February 25, 2026
Explore why early recognition and tailored care are vital for patients with moderate hidradenitis suppurativa. This Dermatology Times piece breaks down key challenges in diagnosis, the real impact on quality of life, and evolving treatment strategies, including when to consider systemic and biologic therapies to prevent disease progression.
Read more
“I Lost 15 Years of My Life”: A Man’s Journey With Hidradenitis Suppurativa
February 25, 2026
In a revealing interview conducted by The Educated Patient, Keven Brown opens up about his long, painful battle with hidradenitis suppurativa — from years of misdiagnosis and physical hardship to the emotional toll of living with a chronic condition and the resilience it took to reclaim his life.
Read more
Do GLP-1 medications help signs and symptoms of Hidradenitis Suppurativa?
February 23, 2026
Could a medication commonly used for type 2 diabetes and weight loss also help improve hidradenitis suppurativa? New research explores the potential impact of GLP-1 receptor agonists on HS signs, symptoms, and quality of life. Click to learn what researchers found and what it could mean for people living with HS.
Read more
Hidradenitis Suppurativa in Patients with Skin of Color: Emerging Therapies and Strategies for Effective Management
January 22, 2026
New insights highlight emerging therapies and practical strategies for managing hidradenitis suppurativa in patients with skin of color. Learn how evolving treatments, improved diagnostic approaches, and patient-centered care are reshaping HS management and addressing long-standing gaps in care.
Read more
Timing, Severity, and Therapeutic Choice in Moderate to Severe HS
January 14, 2026
When should HS treatment escalate? This case-based discussion with HS Foundation board member, Dr. Afsaneh Alavi, explores how timing, severity assessment, and therapeutic choice shape outcomes in moderate to severe hidradenitis suppurativa.
Read more
Beyond the Surface: January 2026
January 13, 2026
Catch the latest from the Hidradenitis Suppurativa Foundation — explore new HS insights, updated wound care resources, SHSA 2026 details, and apply for the Mentored Experience Grant by January 31.
Read more
New HS Health Resources Available on Educated Patient
January 5, 2026
A new Hidradenitis Suppurativa Health Resources Hub is now available on the Educated Patient website, offering clear, evidence-based information on HS risk factors, signs and symptoms, diagnosis, treatment options, and more.
Read more